文献速递神经肿瘤

听神经瘤伽玛刀长期结局:肿瘤稳定支持10年后减少影像监测

Long-term outcomes of Gamma Knife surgery for vestibular schwannomas: tumor stability supports reduced surveillance after 10 years.
PubMed 文献 · J Neurosurg · 2026-05-08

单中心回顾性研究纳入878例散发性听神经瘤患者,评估单次伽玛刀治疗的长期疗效与安全性。中位临床随访154.5个月,5年内无需挽救治疗且随访≥5年的793例患者中,15年累积挽救治疗发生率仅2.1%,真正肿瘤进展仅2例(0.3%),提示10年后可减少或个体化影像监测。

要点

  • 5年内病情稳定者10年后真正进展罕见,可考虑降低影像随访强度。
  • D型肿瘤5年挽救治疗率24.7%,显著高于A–C型的3.6%。
  • 囊性并发症最常见(3.1%),远期仍需按初始肿瘤特征个体化随访。

核心结论

  • 伽玛刀为中小型散发性听神经瘤提供持久的长期肿瘤控制与功能保留。
  • 5年内稳定者10年后未观察到真正肿瘤进展,提示可减少或个体化影像监测。
  • 延迟不良事件仍可发生,随访策略应按初始肿瘤特征与治疗后病程制定。

研究设计与样本

  • 单中心回顾性研究,纳入1991年5月至2020年1月接受单次伽玛刀治疗的散发性听神经瘤患者。
  • 共878例(女性488例,中位年龄57岁);亚组793例(女性438例,中位年龄58岁)为5年内无挽救治疗且随访≥5年者。
  • 肿瘤按改良Koos系统分为A(内听道内)、B(桥小脑角)、C(轻度脑干受压)、D(严重脑干受压伴第四脑室偏移)四型。
  • 中位临床随访154.5个月,评估挽救治疗率、功能结局与不良事件。

主要发现

  • 7.5%的患者需要挽救治疗。
  • D型肿瘤5年挽救治疗发生率24.7%,高于A–C型的3.6%(亚分布风险比2.319,p=0.036)。
  • 稳定亚组15年累积挽救治疗发生率为2.1%,真正肿瘤进展仅2例(0.3%)。
  • 亚组中伽玛刀时肿瘤类型对5年后挽救治疗风险无显著影响。
  • 伽玛刀前Gardner-Robertson 1级听力者10年保留率:晚期(2005–2023)63%,早期(1991–2004)48%。

关键数值与推荐

  • 晚期不良事件:囊性并发症最常见(3.1%),三叉神经痛1.6%,持续性面瘫0.1%,恶性转化0.2%。
  • 稳定亚组15年累积挽救治疗发生率2.1%,真正进展0.3%。
  • D型肿瘤5年挽救治疗率24.7%,A–C型3.6%(亚分布风险比2.319,p=0.036)。

临床怎么用

  • 对中小型散发性听神经瘤,单次伽玛刀可作为长期控制手段。
  • 5年内无挽救治疗且病情稳定者,10年后可减少或个体化常规影像监测频率。
  • D型肿瘤需更密切随访;囊性变、三叉神经痛及恶性转化等延迟事件仍应警惕。

局限性

  • 为单中心回顾性研究,结果外推需谨慎。
  • 亚组分析限定5年内无挽救治疗且随访≥5年,存在选择偏倚可能。
  • 原文未报告前瞻性对照或统一随访影像协议。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study was to evaluate the long-term efficacy and safety of Gamma Knife surgery (GKS) for sporadic vestibular schwannoma (VS), focusing on the durability of tumor control and the necessity of extended posttreatment imaging surveillance. METHODS: This retrospective study included patients with sporadic VS treated with single-session GKS between May 1991 and January 2020 at a single center. Tumors were classified into the following anatomical types using a modified Koos-based system: type A (intracanalicular), type B (cerebellopontine angle), type C (mild brainstem compression), and type D (severe brainstem compression with fourth ventricle deviation). A subgroup analysis in patients without salvage treatment within the first 5 years after GKS and with ≥ 5 years of follow-up was performed to assess long-term stability. Salvage treatment rates, functional outcomes, and adverse events were evaluated. RESULTS: Overall, 878 patients (488 female, median age 57 years) with sporadic VS treated with single-session GKS were included in the analysis. A subgroup of 793 patients (438 female, median age 58 years) remained free of salvage treatment during the first 5 years after GKS and had ≥ 5 years of follow-up. The median clinical follow-up duration was 154.5 months. Salvage treatment was required in 7.5% of the patients, with a significantly higher incidence in patients with type D tumors (24.7% at 5 years) compared with type A-C tumors (3.6%) (subdistribution hazard ratio 2.319, p = 0.036). In the subgroup of patients with stable disease, the cumulative incidence of salvage treatment at 15 years was 2.1%, and true tumor progression was identified in only 2 patients (0.3%). Notably, tumor type at the time of GKS did not significantly influence the risk of salvage treatment beyond 5 years in the subgroup. Serviceable hearing preservation improved in more recent treatment periods: patients with pre-GKS Gardner-Robertson class 1 hearing had a 10-year preservation rate of 63% in the late treatment period (2005-2023) compared with 48% in the early period (1991-2004). Among late adverse events, cyst-related complications were the most common (3.1%), whereas trigeminal neuralgia (1.6%), persistent facial palsy (0.1%), and malignant transformation (0.2%) were infrequent. CONCLUSIONS: GKS provided durable long-term tumor control and functional preservation in patients with small- to medium-sized VS. True tumor progression beyond 10 years was not observed in this cohort, suggesting that the intensity or frequency of routine imaging surveillance can be reduced or individualized after 10 years in patients with stable disease during the first 5 years after GKS. However, because delayed adverse events (e.g., cyst formation, trigeminal neuralgia, and malignant transformation) can still occur, follow-up strategies should be tailored according to initial tumor characteristics and the posttreatment clinical course.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Hasegawa T, Kato T, Mizuno A, et al. Long-term outcomes of Gamma Knife surgery for vestibular schwannomas: tumor stability supports reduced surveillance after 10 years. J Neurosurg. 2026. PMID: 42102400. doi:10.3171/2025.12.JNS252098

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。